Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

PFIZER INC

PFE · NYSE · CIK 0000078003 · Healthcare · Drug Manufacturers—General

INSIDER SIGNAL

67.5 / 100

3 buyers · 3 purchase transaction lines · $3.0M gross purchase

WHY THIS SIGNAL?

Buyer breadthModerate
Purchase sizeStrong
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+21.0 / 35
Purchase size+20.7 / 25
Role+13.0 / 20
Recency+3.3 / 10
Conviction+9.6 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 3 insider(s), not 4+
  • ⚠ Role scores low · most senior buyer: Chairman & CEO (CEO, chair and 10% owners score lowest)
  • ⚠ Purchase activity is becoming less recent

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
DAMICO JENNIFER B.SVP & Controller
▼▼
BOURLA ALBERTChairman & CEO
●
BLAYLOCK RONALD EDirector
●
Buckley Mortimer JDirector
●
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS3
PURCHASE CONCENTRATION34%Largest buyer: BOURLA ALBERT · $1.0M
CLUSTER BUYING · 15D3 insidersPeak activity: 2026-08-05–2026-08-12

Roles in the peak window: Chairman & CEO, Director. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

67.5 / 100

Latest recorded score

↓ -0.2 ptsversus the previous recorded snapshot
  1. 67.9
  2. 67.8
  3. 67.8
  4. 67.7
  5. 67.5

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

3Purchases
2Sales
28Other Form 4 lines
17SEC filings · 365 days
BUYING3 qualifying P line(s) · 180 days
SELLING2 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot detected in parsed evidence

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
+2.3%
3M
+15.5%
6M
+5.1%
12M
+10.1%

Volatility & liquidity

Volatility
24.2%
Beta
—
Avg daily value
USD 1.0B

Valuation

Market cap
USD 161.2B
P/E
20.7×

Fundamentals

Profit margin
12.4%
ROE
9.0%
Industry
Drug Manufacturers—General

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, P/E, Profit margin, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-07-29 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
150,217,617
Previous report
155,202,257
Avg daily volume
34,031,762
Days to cover
4.4

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-12BOURLA ALBERTPurchase (P)Common Stock38,000USD 26.34USD 1,000,920SEC filing ↗
2026-08-05Buckley Mortimer JPurchase (P)Common Stock37,632USD 25.52USD 960,369SEC filing ↗
2026-08-05BLAYLOCK RONALD EPurchase (P)Common Stock39,231USD 25.46USD 998,821SEC filing ↗
2025-02-13BLAYLOCK RONALD EPurchase (P)Common Stock19,457USD 25.65USD 499,072SEC filing ↗
2024-10-30Gottlieb ScottPurchase (P)Common Stock1,000USD 28.24USD 28,240SEC filing ↗
2023-12-15Gottlieb ScottPurchase (P)Common Stock3,000USD 26.47USD 79,410SEC filing ↗
2023-05-08Gottlieb ScottPurchase (P)Common Stock1,000USD 38.58USD 38,580SEC filing ↗
2023-05-05Gottlieb ScottPurchase (P)Common Stock1,000USD 38.43USD 38,430SEC filing ↗
2020-08-06BLAYLOCK RONALD EPurchase (P)Common Stock13,000USD 38.55USD 501,085SEC filing ↗
2020-01-30Gottlieb ScottPurchase (P)Common Stock1,000USD 37.00USD 37,000SEC filing ↗

Form 4 evidence

33 transaction lines in the latest 365-day window; 527 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-12BOURLA ALBERTPurchase (P)Common Stock38,000USD 26.34USD 1,000,920SEC filing ↗
2026-08-05DAMICO JENNIFER B.Sale (S)Common Stock3,278USD 25.40USD 83,261SEC filing ↗
2026-08-05Buckley Mortimer JPurchase (P)Common Stock37,632USD 25.52USD 960,369SEC filing ↗
Show recent Form 4 evidence (26 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-12BOURLA ALBERTPurchase (P)Common Stock38,000USD 26.34USD 1,000,920SEC filing ↗
2026-08-05DAMICO JENNIFER B.Sale (S)Common Stock3,278USD 25.40USD 83,261SEC filing ↗
2026-08-05Buckley Mortimer JPurchase (P)Common Stock37,632USD 25.52USD 960,369SEC filing ↗
2026-08-05BLAYLOCK RONALD EPurchase (P)Common Stock39,231USD 25.46USD 998,821SEC filing ↗
2026-06-09DAMICO JENNIFER B.Sale (S)Common Stock2,000USD 25.70USD 51,400SEC filing ↗
2026-03-04DAMICO JENNIFER B.Tax withholding (F)Common Stock826USD 26.62USD 21,988SEC filing ↗
2026-03-03DAMICO JENNIFER B.Award / grant (A)Common Stock21,719USD 0.00USD 0SEC filing ↗
2026-02-27DAMICO JENNIFER B.Tax withholding (F)Common Stock655USD 27.65USD 18,111SEC filing ↗
2026-02-26McDermott MichaelTax withholding (F)Common Stock3,503USD 27.10USD 94,931SEC filing ↗
2026-02-25SAHNI PAYALOption exercise / conversion (M)Common Stock56,888USD 33.82USD 1,923,952SEC filing ↗
2026-02-25SAHNI PAYALTax withholding (F)Common Stock55,149USD 26.92USD 1,484,795SEC filing ↗
2026-02-25McDermott MichaelOption exercise / conversion (M)Common Stock37,925USD 33.82USD 1,282,624SEC filing ↗
2026-02-25McDermott MichaelTax withholding (F)Common Stock36,723USD 26.92USD 988,699SEC filing ↗
2026-02-25LANKLER DOUGLAS MOption exercise / conversion (M)Common Stock122,907USD 33.82USD 4,156,715SEC filing ↗
2026-02-25LANKLER DOUGLAS MTax withholding (F)Common Stock119,009USD 26.92USD 3,204,096SEC filing ↗
2026-02-25Fonseca LidiaOption exercise / conversion (M)Common Stock56,888USD 33.82USD 1,923,952SEC filing ↗
2026-02-25Fonseca LidiaTax withholding (F)Common Stock55,124USD 26.92USD 1,484,118SEC filing ↗
2026-02-25DAMICO JENNIFER B.Option exercise / conversion (M)Common Stock17,558USD 33.82USD 593,812SEC filing ↗
2026-02-25DAMICO JENNIFER B.Tax withholding (F)Common Stock17,048USD 26.92USD 458,994SEC filing ↗
2026-02-25BOURLA ALBERTOption exercise / conversion (M)Common Stock491,626USD 33.82USD 16,626,791SEC filing ↗
2026-02-25BOURLA ALBERTTax withholding (F)Common Stock475,544USD 26.92USD 12,803,056SEC filing ↗
2026-02-25BOSHOFF CHRISTOFFELTax withholding (F)Common Stock6,833USD 27.09USD 185,106SEC filing ↗
2026-02-25BOSHOFF CHRISTOFFELAward / grant (A)Common Stock13,383USD 0.00USD 0SEC filing ↗
2026-02-23DAMICO JENNIFER B.Tax withholding (F)Common Stock419USD 27.06USD 11,338SEC filing ↗
2026-02-23BOSHOFF CHRISTOFFELTax withholding (F)Common Stock816USD 27.06USD 22,081SEC filing ↗
2026-01-30BOSHOFF CHRISTOFFELTax withholding (F)Common Stock12,887USD 26.44USD 340,732SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerPFE
CIK0000078003
SectorHealthcare
IndustryDrug Manufacturers—General Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNYSE

Data coverage

Local Form 4 history527 transaction lines from 2020-01-30 to 2026-08-12
15 P purchase lines · 96 S sale lines · 416 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.